[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infertility-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infertility-treatment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,84,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100410056","biomarkers-of-endometrial-receptivity-100410056",false,"NCT04619524","Biomarkers of Endometrial Receptivity","Biomarkers of Endometrial Receptivity: A Prospective Multicenter Study on Proteomic Biomarkers of Endometrial Receptivity in Cervical Mucus ( PRO BIOMER - CM )","BIOMER","Inclusion Criteria - Arm A - stimulated cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* follicle stimulating hormone (FSH) \\\u003C 10 IU\u002FL on the third day\n* basal antral follicle count of 5-15\n* undergoing the same routine gonadotrophin-releasing hormone agonist (GnRHa) long depot or gonadotrophin-releasing hormone antagonist (GnRH-ant.) protocol\n* informed consent\n\nExclusion Criteria - Arm A - stimulated cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria)\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 1.0 mIU\u002Fml or more than 20 oocytes, milli-International unit (mIU)\n* previous ovarian hyperstimulation syndrome (OHSS)\n* presence of any structural abnormality of the reproductive system\n* donor oocyte cycles\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL\n* low response to stimulation\n* endometrium \\\u003C 8 mm at the day of human chorionic gonadotropin (hCG) or ET\n* number of retrieved oocytes 5 - 20\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* OHSS\n* IVF cycle cancelled before ET\n* other than easy one high-quality blastocyst transfer (at least grade 3BB)\n\nInclusion criteria - Arm B - substituted cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder at stimulation\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* FSH \\\u003C 10 IU\u002FL on the third day\n* undergoing the same routine estrogen\u002Fprogesterone substituted cycle\n* informed consent\n\nExclusion criteria - Arm B - substituted cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders such as diabetes, metabolic syndrome, and thyroid disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria), hyperprolactinaemia\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 0.5 mIU\u002Fml in the stimulated cycle\n* previous OHSS\n* presence of any structural abnormality of the reproductive system\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL in the stimulated cycle\n* number of retrieved oocytes 5 - 20 in the stimulated cycle\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* endometrium less than 8 mm at the day of thawing and transfer indication\n* thawed blastocyst cycle cancelled before ET\n* other than easy one best quality frozen\u002Fthawed blastocyst transfer (at least grade 3BB)","FEMALE","36 Years",{"count":20,"type":21},476,"ESTIMATED","INTERVENTIONAL",[24],"NA","Analysis of proteins from cervical mucus will be done in patients undergoing infertility treatment (fresh or frozen embryo transfer). Cervical mucus will be analysed for potential new biomarkers of endometrium receptivity. Comparison of the peptide spectrum will be done for the pregnant and not pregnant patients.",[27,28,29,30],"IVF","Infertility Treatment","Fertility Disorders","Embryo Transfer",[32,33,34,35,36,37,38,39,40],"cervix","mucus","endometrium","receptivity","biomarker","proteomics","infertility","in-vitro","fertilisation","RECRUITING","2026-03-19",{"date":44,"type":45},"2026-03-20","ACTUAL",{"date":47,"type":45},"2018-05-01",{"date":49,"type":21},"2026-12-31",{"name":51,"class":52},"The Institute of Molecular and Translational Medicine, Czech Republic","OTHER",3,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":17,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100628471","phase-4-effect-clomiphene-vs-clomiphene-along-with-pioglitazone-on-ovarian-stimulation-rate-100628471","NCT07462065","Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate","Comparison of Clomiphene Citrate vs Clomiphene Citrate in Combination With Pioglitazone in Terms of Ovarian Stimulation and Pregnancy Rates Among Infertile Women Suffering From Polycystic Ovarian Syndrome","Inclusion Criteria:\n\nNormal hysterosalpingography Normal spermogram Suffering from PCOS Ovarian cysts less than 20mm.\n\nExclusion Criteria:\n\nHistory of chronic cardiovascular disease Chronic kidney disease Diabetes Thyroid disease Pulmonary disease",true,"18 Years","38 Years",{"count":65,"type":21},62,[67],"PHASE4","Women who meet the study requirements will be enrolled and randomly assigned by a computer system to receive either pioglitazone 30 mg daily or a placebo starting from the second day of their menstrual period for the same duration. All participants will also take clomiphene citrate 150 mg daily from day 3 to day 7 of the menstrual cycle. A transvaginal ultrasound will be performed on day 10 of the menstrual cycle to assess the growth of ovarian follicles, and the number of mature follicles (16-24 mm) will be recorded. If at least one mature follicle measuring 16-24 mm is present and the endometrial thickness is at least 7 mm, an injection of human chorionic gonadotropin (hCG) will be given to trigger ovulation, followed by an intrauterine insemination (IUI) procedure. Participants will be followed until the end of the menstrual cycle, and if the menstrual period is delayed by 5 days, a blood test for β-hCG will be performed to confirm pregnancy. Any side effects during the treatment period, such as swelling, fluid retention, blurred vision, or weight gain, will be recorded.",[28,70],"Pregnancy Rates",[72,73],"Clomiphene citrate","Pioglitazone","2026-03-04",{"date":76,"type":45},"2026-03-10",{"date":78,"type":45},"2026-03-01",{"date":80,"type":21},"2026-06-01",{"name":82,"class":52},"PAEC General Hospital, Islamabad",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":83},"100607220","phase-4-ketorolac-use-and-fresh-embryo-transfer-outcomes-100607220","NCT07185724","Ketorolac Use and Fresh Embryo Transfer Outcomes","Balancing Comfort and Success: Post-retrieval Ketorolac in Fresh Embryo Transfers","Inclusion Criteria:\n\n* IVF utilizing autologous oocytes and all sperm sources\n* IVF cycles utilizing ICSI and standard insemination\n* Plan to transfer embryo on day 5\n* BMI below 50\n\nExclusion Criteria:\n\n-allergies or medical contraindications to NSAIDs","37 Years",{"count":93,"type":21},200,[67],"Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy.\n\nHowever, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle).\n\nDespite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research.\n\nThis study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would.\n\nPrimary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia.\n\nSecondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w\u002Fin 24 hours for pain\u002Fbleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.",[97,28,98,99,100],"Infertility (IVF Patients)","Post-op Pain","Fresh Embryo Transfer","Oocyte Retrieval and Post Operative Pain Control",[27,102,103,104,105,106,107,108,109],"post operative pain control","oocyte retrieval","fresh embryo transfer","ketorolac","toradol","implantation rate","live birth rate","miscarriage rate","2025-12-11",{"date":112,"type":45},"2025-12-15",{"date":114,"type":45},"2025-11-08",{"date":116,"type":21},"2028-09-01",{"name":118,"class":52},"Jessica D. Kresowik",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100615181","prevalence-of-violence-against-infertile-women-attending-infertility-treatment-100615181","NCT07289269","Prevalence of Violence Against Infertile Women Attending Infertility Treatment","Inclusion Criteria:\n\n* Married women with primary or secondary infertility due to male or female factors at reproductive age (18-45 years).\n\nExclusion Criteria:\n\n* • women who refused to participate in the study.\n\n  * Separated or divorced women.","45 Years",{"count":127,"type":21},233,"OBSERVATIONAL","Infertility is a major health concern with a great psychosocial impact. It's defined as the inability to achieve pregnancy after 12 months or more of regular unprotected sexual intercourse\\[1\\] affecting about 12%-25% of couples in Egypt\\[2, 3\\].\n\nPeople in Egypt prefer extended families to guarantee maintained family line. Therefore, infertility leads to great negative attitudes and extreme pressures on women\\[4\\].\n\nBesides the medical advances in the treatment of infertility as a pathological condition, concerted actions should be taken to address the consequences of infertility on other aspects of human wellbeing including violence against infertile women\\[1\\].\n\nInfertile women are more vulnerable to depression and stress which are the underlying factors for domestic violence, as they are commonly blamed for this issue. Domestic violence against women is a global public health problem and human rights crime\\[5\\]. In 2013, the World Health Organization (WHO) released a report providing global and regional estimates of violence against women, which documented the broad and invasive global prevalence of this problem and its impact on many aspects of women's health\\[6\\]. Intimate partner violence is the most common form of violence against women, defined as any form of violence by a current or former male intimate partner that can include emotional\u002Fpsychological and economic elements in addition to physical and sexual components. In the most recent WHO report on IPV and its consequences for health, The baseline quality of life of the victims of intimate partner violence is significantly impaired when compared with the non-abused controls \\[7\\]. the analysis was limited to physical and\u002For sexual violence because these are the most widely documented manifestations of IPV across studies\\[8\\].\n\nThis study will be conducted in collaboration with National Women's council and UNFPA Egypt .We are already running a safe women clinic at Women Health Hospital Assiut university since March 2021 aiming to keep women safe and guarding against any type of violence We will conduct this study to evaluate the relation between infertility and violence against Egyptian women. We hypothesized that infertile women would suffer more violance than fertile ones.",[28],"NOT_YET_RECRUITING","2025-12-04",{"date":134,"type":45},"2025-12-17",{"date":136,"type":21},"2025-12",{"date":138,"type":21},"2027-12",{"name":140,"class":52},"Assiut University"]